发表在杂志Allergy上的一项研究报告中，来自米兰Sacco医院的研究者通过研究表示，对于利用高效抗逆转录病毒疗法（HAART）治疗的草花粉过敏的HIV阳性患者而言，舌下脱敏治疗（sublingual immunotherapy，SLIT）或许可以给患者带来较为明显的临床效益。
  研究者Enrico Iemoli表示，文章中我们对HAART治疗的草花粉过敏的HIV阳性患者进行研究，检测了SLIT疗法对患者的安全性及临床疗效；通过将13名接受SLIT药片治疗的患者同利用系统性疗法治疗的9名患者进行对比，研究者利用综合得分（TCS）、总的药物症状分值及生活质量（QoL）的调查问卷来评估患者的临床治疗效果。
  研究者发现，SLIT治疗的患者相比临床对照者而言表现出了明显的疾病改善迹象（TCS：P=0.0001；QoL：P=0.03），任何一组患者机体的CD4细胞量和病毒载量并没有发生明显变化。
  最后研究者指出，这项研究是我们对少量HIV阳性患者进行了一项前期研究，研究结果不仅证实了SLIT疗法的临床疗效，同时还说明这种疗法是安全的，而且并不会改变患者机体任何的免疫病毒学参数。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的原文摘要：

Sublingual Allergen Immunotherapy in HIV positive patients
Allergy    DOI: 10.1111/all.12713
Enrico Iemoli*, Linda Borgonovo, Alessandra Fusi, Carlo Magni, Elena Delfina Ricci, Giuliano Rizzardini andStefania Piconi
HIV infection is a relative contraindication for allergic immunotherapy (AIT). In the last decade highly active antiretroviral therapy (HAART) has improved immune function and life expectancy in HIV infected patients whose respiratory allergies incidence is similar to the general population.
We evaluated the safety and clinical effectiveness of sublingual immunotherapy in a group of grass-pollen allergic HAART treated HIV-positive patients. Thirteen patients received sublingual immunotherapy (SLIT) tablet (Oralair, Stallergenes©) and symptomatic therapy and were compared with nine receiving symptomatic therapy alone. Clinical benefits were evaluated by analysis of total combined score (TCS), sum of symptom-medication score and a quality of life (QoL) questionnaire. HIV viral load and peripheral TCD4 lymphocytes were analyzed at the beginning and the end of the study. Clinical efficacy data showed a significant improvement in SLIT treated patients compared to controls (TCS: p=0.0001; QoL: p= 0.03). We did not observe a significant alteration of TCD4 cells counts and viral load (VL) in both groups.

（转化医学网360zhyx.com）